Protein higher order structure (secondary, tertiary and quaternary structure) determination in accordance with FDA, EMEA and ICH Guidance (Q6B, Q5E)
Protein higher order structure (HOS) analysis is a key component in defining a biologic’s critical quality attributes (CQAs) and understanding the molecular structure of a protein and forms a central requirement of the ICH Q6B guideline: Test Procedures and Acceptance Criteria for Biological Products.
Changes in higher order structure can impact quality, stability, safety and efficacy of biopharmaceutical products with increased potential for immunogenicity and loss of biological function. As such analytics are required to measure and monitor secondary, tertiary and quaternary protein structure during early and late phase characterization, and also as part of comparability studies (ICH Q5(E)).
A number of analytical approaches can be applied which must be able to determine if a change in higher order structure is apparent. If specific changes in quality attributes are expected as a result of a process change (e.g., modification of a chromatographic purification step), new analytical methods, above and beyond those used previously, might be required in order to capture all pertinent information about higher order structure.
Our biologics characterisation group provides higher-order structure analysis via a suite of orthogonal techniques including far and near-UV circular dichroism (CD) which provides information regarding secondary (α-helix, β-sheet and random coil structures) and tertiary structure, respectively. Fourier transform infrared spectroscopy (FTIR) also provides information on the secondary structure as can 1D and 2D nuclear magnetic resonance spectroscopy (NMR) and fluorescence spectroscopy. We examine the secondary and tertiary structures of protein in “normal “presentation as well as a function of temperature and pH allowing the study of subtle structure changes that may occur during processing, storage or handling.
Higher order structural characterization methods
The HOS data we generate can assist you during formulation development, stability studies, comparability and process development. In addition, techniques to study protein aggregation are important. We deploy dynamic light scattering (DLS), size-exclusion chromatography (SEC) and analytical ultracentrifugation (SV-AUC) to meet regulator’s expectations of orthogonal methods.
The relationship between higher-order structure and biological activity is of increasing importance. Potency testing is the quantitative measure of biological activity and we offer cell-based bioassays by measuring the product’s physiological response.
Higher Order Structure Analysis for Biosimilars
There is a regulatory expectation that, as part of the demonstration of biosimilarity during development, a comparative side-by-side HOS analysis is conducted between the biosimilar and innovator. Our programs incorporate several methods (such as CD, NMR and FTIR) with expert data interpretation to facilitate assessment of comparative analytical characterization data across multiple lots of both biosimilar and innovator (reference) product in order to evaluate variability of quality attributes.
Comprehensive protein characterisation from one source
With an in-depth knowledge of the current regulatory expectations for higher order structure analysis and expertise across multiple techniques our scientists design and deliver strategic phase appropriate analytics required to support characterisation, CMC protein analysis support, comparability, stability testing, regulatory submissions and ongoing batch release analysis.
Need help or have a question?